[ad_1]
The report by Persistence Market Research focuses on the factors influencing the current scenario of the "non-alcoholic fatty liver disease treatment market". The research report also proposes a concise badysis that refers to the marketing, profit estimation and market size aspects of the sector. In addition, the report highlights the competitiveness of the key players in the projection schedule, which also includes their portfolios and their expansion efforts.
Fatty liver disease refers to the accumulation of fat (triglycerides) in the liver. The liver cell contains fats, but excess fat accumulation can be a cause for concern and can lead to inflammation of the liver called steatohepatitis. Foie gras can be caused by alcohol and can be nonalcoholic. Steatohepatitis can cause cirrhosis of the liver (fibrosis, scarring and hardening of the liver). The cause of non-alcoholic fatty liver disease (NAFLD) is unknown. Non-alcoholic fatty liver disease (NAFLD) is one of the most common diseases in the United States. The prevalence of NAFLD is increasing due to the increased prevalence of diabetes and obesity. According to a National Health and Nutrition Examination survey, about 20 to 30% of the population in the western world suffers from non-alcoholic fatty liver disease (NAFLD). Common symptoms include fatigue, weakness, weight loss and others. The diagnosis of NAFLD requires the combination of different tests, such as a blood test, an ultrasound, a CT scan, an MRI and a liver biopsy. Both types of non-alcoholic fatty liver disease (NAFLD) include simple fatty liver disease and non-alcoholic steatohepatitis (NASH). Single fatty liver is a type of non-alcoholic fatty liver (NAFL) in which fat is deposited, but no inflammation or damage to the liver is observed. NASH is an inflammation of the liver due to excess fat and can lead to liver damage and disease.
Get an example copy of Report @ https://www.persistencemarketresearch.com/samples/22498
In 2014, according to the World Health Organization (WHO), about 422 million of the adult population had diabetes compared to about 108 million in 1980. The global prevalence of diabetes is increasing, with an overall prevalence of 4, 7% in 1980 to 8.5% in 2014. As a result, the increasing prevalence of diabetes and obesity is a major contributor to the growth of market earnings of treating non-alcoholic fatty liver disease through the world. Availability of the extended product range as the main players in the global market for non-alcoholic fatty liver disease introduce innovative and expanded range products to maintain their market share, the development of clinical trials leading to the development of new products. product approval and revenue generation. Manufacturers and organizations such as the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institutes of Health (NIH) participate in research and development activities and support research on various diseases. These are some of the factors that are driving growth in the treatment of NAFLD.
The global market for non-alcoholic fatty liver disease is segmented by product type, end-user and geography
Segment by product type
- antioxidants
- thiazolidinedione
- biguanides
- Lipid-lowering agents
- FXR receiver agonist
- Other
Segment by channel of distribution
- Hospital pharmacy
- Retail Pharmacy
- drugstores
- Online pharmacy
- Other
The global market for non-alcoholic fatty liver disease is segmented by product type and distribution channel. Based on the type of product, the market is segmented into antioxidants, thiazolidinedione, biguanides, lipid-lowering agents, FXR receptor agonist and other drugs used in the treatment of non-alcoholic fatty liver disease. According to national health and nutrition surveys conducted between 2009 and 2010, the prevalence of NASH is about 3% in the general population in the United States and about 25% in obese people. Thiazolidinedione and metformin are widely used for non-alcoholic liver diseases (NAFLD), thiazolidinedione and metformin are expected to gain a larger share among other types of products and contribute to the growth of the global market for the treatment of cancer. non-alcoholic fatty liver disease.
By geography, the global market for non-alcoholic fatty liver disease is segmented into five major regions, namely: North America, Latin America, Europe, Asia-Pacific and Middle East and Africa. It is estimated that North America is leading the global market for treating non-alcoholic fatty liver disease due to the increased prevalence of diabetes and cardiovascular disease in the United States. There are a large number of manufacturers on the market, with a large number of customers. The Asia-Pacific market is also expected to experience strong growth in the near future due to factors such as increased health care spending, improved living standards, the change of lifestyle funding for the acceleration of research and development activities.
Pfizer Inc., Hoffmann-La Roche Ltd., Daewoong Co., Ltd., Cardax, Inc., Merck & Co., Inc., Novartis AG, Gilead Sciences, Inc., AstraZeneca plc., Limerick BioPharma, Inc., GW Pharmaceuticals, Allergan, Plc., Takeda Pharmaceutical Company Ltd. and others
Request customization of this report @ https://www.persistencemarketresearch.com/request-customization/22498
The report covers a comprehensive badysis of:
- Non-alcoholic fatty liver disease treatment Market Segments
- Dynamics of the market for the treatment of non-alcoholic fatty liver diseases
- Actual size of the historical market, 2013 – 2015
- Treatment of non-alcoholic fatty liver diseases Market size and forecasts 2016 to 2024
- Market for non-alcoholic fatty liver diseases Current Trends / Problems / Challenges
- Competition and companies involved
- Treatment of non-alcoholic fatty liver disease Market factors and constraints
Regional badysis includes
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Highlights of the report:
- Changing industrial dynamics
- In-depth segmentation of the market
- Historical, current and projected size of the industry Recent trends in the industry
- Key competition landscape
- Strategies of key players and product offerings
- Potential and niche segments / regions showing promising growth
- A neutral perspective of market performance
Source link
